Effectiveness of Exosome Treatment in Androgenetic Alopecia: Outcomes of a Prospective Study

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This review discusses the criteria for evaluating treatments for androgenetic alopecia and emphasizes the importance of shared decision-making, noting no treatment currently meets all desired criteria of efficacy, safety, affordability, and ease of use.

This review identified that baricitinib increases both short- and long-term hair regrowth in patients with alopecia areata compared to placebo, but found inconclusive results for serious adverse effects, while evidence for other treatments remains very uncertain.

This study observed that in a mouse model of androgenetic alopecia, treatments with LTF, 5% minoxidil, and LTF-DPC-EXO significantly promoted hair regeneration compared to the model group, potentially through modulation of the PI3K/AKT signaling pathway.

This review discusses educational activities for dermatologists on diagnosing and managing different types of hair loss and reports no new clinical results; it emphasizes improving clinical skills for alopecia treatment.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review discusses the effectiveness of adipose-derived stem cells in treating alopecia, reporting on various clinical studies but presenting no new clinical results.

This study reports that hair follicle-derived mesenchymal stem cells significantly reduced hair loss and inflammation in alopecia areata models, suggesting a potential therapeutic approach.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

In a mouse model, this study demonstrated that a microneedle patch system using keratin and integrated with MSC-derived exosomes and UK5099 promoted hair regrowth more efficiently than traditional delivery methods.

This study suggests that exosomes derived from dermal papilla cells, especially those cultured in three dimensions, promote hair growth and regeneration by enhancing follicular cell activity.

This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.

This study found that treatment with mesenchymal stem cell extracellular vesicles enhanced hair growth in mice and stimulated dermal papilla cell activity and growth factor production in vitro.

This retrospective study found that adipose-derived stem cell-conditioned media increased hair density and thickness in women with female pattern hair loss over 12 weeks, with no severe adverse effects reported.

This study found that intradermal adipocyte lineage cells in mice are necessary and sufficient to activate follicular stem cells, highlighting their role in regulating skin stem cell activity.

This study developed a standardized questionnaire to measure patient-perceived changes in hair growth and appearance, which showed significant favoring of active treatment over placebo in a clinical trial for male androgenetic alopecia.